MedTrace Logo

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

NCT05334147 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2022-04-19

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of anlotinib combined with chemotherapy treatment for patients with HER2 negative advanced breast cancer previously received anthracyclines and taxanes

Conditions

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Yongmei Yin · The First Affiliated Hospital with Nanjing Medical University

  • Wei Li · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2025-02-01
Completion
2025-09-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05334147 on ClinicalTrials.gov